Drug Interactions between erlotinib and vimseltinib
This report displays the potential drug interactions for the following 2 drugs:
- erlotinib
- vimseltinib
Interactions between your drugs
erlotinib vimseltinib
Applies to: erlotinib and vimseltinib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with vimseltinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. The proposed mechanism, based on in vitro data, involves decreased clearance due to inhibition of P-gp by vimseltinib. Based on model-informed drug interaction studies, coadministration of the P-gp substrate dabigatran with vimseltinib (30 mg twice weekly) is predicted to increase the systemic exposure (AUC) and peak plasma concentration (Cmax) of dabigatran by 2 to 3-fold. However, if dabigatran is administered 4 hours after vimseltinib (30 mg twice weekly), the AUC and Cmax are predicted to increase by only up to 1.3-fold. Clinical data are not available.
MANAGEMENT: Concomitant use of vimseltinib with P-gp substrates should generally be avoided. If coadministration is considered necessary, vimseltinib should be taken at least 4 hours prior to the P-gp substrate. The individual product labeling of the P-gp substrate should be consulted for further guidance.
Drug and food interactions
erlotinib food
Applies to: erlotinib
Erlotinib should be taken on an empty stomach at least 1 hour before or 2 hours after a meal and at the same time each day unless otherwise directed by your doctor. You should also avoid grapefruit and grapefruit juice while taking erlotinib. Food and grapefruit juice can increase the absorption of erlotinib from the gastrointestinal tract, which may lead to higher blood levels of the medication and possibly increased side effects. If you are a smoker, you should try to quit as soon as you can. Cigarette smoking can reduce the blood levels of erlotinib, which may make the medication less effective in treating your cancer. It is best to avoid smoking during erlotinib therapy. Talk to a healthcare professional if you have any questions or concerns. If you start smoking or undergo smoking cessation, your doctor may need to adjust your dose of erlotinib. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.